CohBar, Inc. (NASDAQ:CWBR) is reporting third quarter earnings results on Monday 16th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.07 per share.
For the full year, analysts predict loss of $ 0.33 per share.
Stock Performance
On Friday, shares of CohBar, Inc. has traded high as $ 1.10 and has cracked $ 1.03 on the downward trend, reaching $ 1.09 with volume of 450.70 thousand shares.
According to the previous trading day, closing price of $ 1.09, representing a 21.18 % increase from the 52 week low of $ 0.85 and a 75.76 % decrease over the 52 week high of $ 4.25.
The company has a market capital of $ 63.18 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, initiated by WBB Securities at Speculative Buy rating, with $ 4.50 target price.
- On 17th September 2020, initiated by Roth Capital at Buy rating, with $ 8.00 target price.
Conference Call
CohBar, Inc. will be hosting a conference call at 5:00 PM eastern time on 16th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (877) 451-6152 Toll Free or (201) 389-0879 Toll Number, when prompted, enter passcode 13711606 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.cohbar.com
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular disease, and neurodegenerative disease, such as Alzheimers disease. Its lead MBT candidate is CB4211, a novel optimized analog of the MOTS-c mitochondrial-derived peptide for the treatment of NASH and obesity.
